Neurelis, Inc. ("Company"), today announced a transaction with OrbiMed for the sale of the Company's rights, royalty ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ARS Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing solutions for patients with allergic reactions, particularly anaphylaxis, through innovative products like their ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...

The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...

We are convinced that neffy® will transform anaphylaxis, benefitting patients at risk and leading to a significant expansion of the market.” Exclusive rights to new indications ARS Pharma is ...

The European Commission granted EURneffy® (the trade name for neffy® in the EU) market authorisation in the EU in August 2024. Furthermore, neffy® was approved by the US Food and Drug ...